<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39327745</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1747-6356</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Expert review of respiratory medicine</Title><ISOAbbreviation>Expert Rev Respir Med</ISOAbbreviation></Journal><ArticleTitle>The unique metabolic and lipid profiles of patients with severe COVID-19 compared to severe community-acquired pneumonia: a potential prognostic and therapeutic target.</ArticleTitle><Pagination><StartPage>815</StartPage><EndPage>829</EndPage><MedlinePgn>815-829</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/17476348.2024.2409264</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Compare the changes and differences in metabolome and lipidome profiles among severe COVID-19 and CAP patients with ARF to identify biomarkers that could be used for personalized diagnosis, prognosis, and treatment.</AbstractText><AbstractText Label="RESEARCH DESIGN AND METHODS" NlmCategory="UNASSIGNED">Plasma samples were taken at hospital admission (baseline) and on the 5<sup>th</sup> day of hospitalization (follow-up) and examined by RP-LC-QTOF-MS and HILIC-LC-QTOF-MS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">127 patients, 17 with CAP and 110 with COVID-19, were included. The analysis revealed 87 altered metabolites, suggesting changes in the metabolism of arachidonic acid, glycerolipids, glycerophospholipids, linoleic acid, pyruvate, glycolysis, among others. Most of these metabolites are involved in inflammatory, hypoxic, and thrombotic processes. At baseline, the greatest differences were found in phosphatidylcholine (PC) 31:4 (<i>p</i> &lt; 0.001), phosphoserine (PS) 34:3 (<i>p</i> &lt; 0.001), and phosphatidylcholine (PC) 36:5 (<i>p</i> &lt; 0.001), all of which were notably decreased in COVID-19 patients. At follow-up, the most dysregulated metabolites were monomethyl-phosphatidylethanolamine (PE-Nme) 40:5 (<i>p</i> &lt; 0.001) and phosphatidylcholine (PC) 38:4 (<i>p</i> &lt; 0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Metabolic and lipidic alterations suggest inhibition of innate anti-inflammatory and anti-thrombotic mechanisms in COVID-19 patients, which might lead to increased viral proliferation, uncontrolled inflammation, and thrombi formation. Results provide novel targets for predictive biomarkers against CAP and COVID-19.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="UNASSIGNED">Not applicable.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ibáñez-Prada</LastName><ForeName>Elsa D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Unisabana Center for Translational Science, Universidad de La Sabana Chía, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clínica Universidad de La Sabana Chía, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guerrero</LastName><ForeName>Jose L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>MetCore-Metabolomics Core Facility, Vice-Presidency of Research and Knowledge Creation, Universidad de Los Andes, Bogotá, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bustos</LastName><ForeName>Ingrid G</ForeName><Initials>IG</Initials><AffiliationInfo><Affiliation>Unisabana Center for Translational Science, Universidad de La Sabana Chía, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>León</LastName><ForeName>Lizeth</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>MetCore-Metabolomics Core Facility, Vice-Presidency of Research and Knowledge Creation, Universidad de Los Andes, Bogotá, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuentes</LastName><ForeName>Yuli V</ForeName><Initials>YV</Initials><AffiliationInfo><Affiliation>Unisabana Center for Translational Science, Universidad de La Sabana Chía, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santamaría-Torres</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>MetCore-Metabolomics Core Facility, Vice-Presidency of Research and Knowledge Creation, Universidad de Los Andes, Bogotá, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Restrepo-Martínez</LastName><ForeName>Juan M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Unisabana Center for Translational Science, Universidad de La Sabana Chía, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano-Mayorga</LastName><ForeName>Cristian C</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0001-8344-0535</Identifier><AffiliationInfo><Affiliation>Clínica Universidad de La Sabana Chía, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendez</LastName><ForeName>Lina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clínica Universidad de La Sabana Chía, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez-Duque</LastName><ForeName>Salome</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unisabana Center for Translational Science, Universidad de La Sabana Chía, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santacruz</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Fundación Santa Fe de Bogotá, Bogotá, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Critical Care Department, Instituto de Ensino e Pesquisa do Pará, Brasil - IEPPA, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conway-Morris</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3211-3216</Identifier><AffiliationInfo><Affiliation>Division of Anesthesia, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martín-Loeches</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-5834-4063</Identifier><AffiliationInfo><Affiliation>Department of Clinical Medicine, St James's Hospital, Multidisciplinary Intensive Care Research Organization (MICRO), Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez-Juarbe</LastName><ForeName>Norberto</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Genomic Medicine Group, J Craig Venter Institute, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cala</LastName><ForeName>Mónica P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>MetCore-Metabolomics Core Facility, Vice-Presidency of Research and Knowledge Creation, Universidad de Los Andes, Bogotá, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyes</LastName><ForeName>Luis Felipe</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Unisabana Center for Translational Science, Universidad de La Sabana Chía, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clínica Universidad de La Sabana Chía, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pandemic Sciences Institute, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Respir Med</MedlineTA><NlmUniqueID>101278196</NlmUniqueID><ISSNLinking>1747-6348</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017714" MajorTopicYN="Y">Community-Acquired Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081362" MajorTopicYN="N">Lipidomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055442" MajorTopicYN="N">Metabolome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Community-acquired pneumonia</Keyword><Keyword MajorTopicYN="N">Intensive Care</Keyword><Keyword MajorTopicYN="N">lipid profile</Keyword><Keyword MajorTopicYN="N">metabolomic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>1</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39327745</ArticleId><ArticleId IdType="doi">10.1080/17476348.2024.2409264</ArticleId></ArticleIdList></PubmedData></PubmedArticle>